Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Pelthos Therapeutics Inc.AMEX: PTHS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 3.31M shares rose 440.4% year over year, ahead of the +227.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.0% from the prior quarter. Over 3 fiscal years it compounded at +48.3% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +440.4% holds above the trailing-twelve-month pace of +227.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
3.31M+5.0% QoQ
Last fiscal yearDec 2025
1.88M+220.0% YoY
LTMMar 2026
1.94M+227.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+440.4%——
1 year+220.0%——
3-year CAGR+48.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.88M USD
Year-over-year change
+220.0%
4-year CAGR
+34.4%

Weighted Avg Shares vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 weighted avg shares of 1.94M shares is the 3rd highest of the 4 companies compared; the peer median is 5.17M shares.
  • Its year-over-year change of +227.5% is the 2nd highest of 4, against a peer median of +53.1%.
  • Over three fiscal years its annual growth of +48.3% compares with a peer median of +56.6%.
PTHS Competitors Peer median
Weighted Avg Shares for PTHS and competitors
Company Period LTM YoY 3-year CAGR
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 202617.05M +639.7%+212.8%
CINGCingulate Inc.LTM Mar 20265.17M +53.1%+56.6%
PTHSPelthos Therapeutics Inc.LTM Mar 20261.94M +227.5%+48.3%
ENLVEnlivex Therapeutics Ltd.LTM Dec 20251.92M +41.5%+35.4%
Peer median (excluding PTHS) 5.17M+53.1%+56.6%

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000016.8M
Cost of Revenue00009.37M
Gross Profit00007.43M
Gross Margin————44.2%
Research & Development209.05K391.73K2.58M1.18M1.23M
Selling, General & Admin629.95K1.93M4.28M6.39M37.08M
Operating Expenses839K2.32M6.86M7.57M39.86M
Depreciation & Amortization00002.29M
EBITDA(595.13K)(2.32M)(6.86M)(7.17M)(45.41M)
EBITDA Margin————-270.4%
Operating Income(839K)(2.32M)(6.86M)(7.57M)(32.43M)
Operating Margin————-193.1%
Interest Income00005K
Interest Expense253140.43K518.51K786.39K3.01M
Other Income / Expenses243.61K(140.43K)(518.51K)(383.89K)(18.28M)
Income Before Tax(595.39K)(2.46M)(7.38M)(7.96M)(50.71M)
Pre-Tax Margin————-301.9%
Income Tax Expense0000(7.39M)
Net Income(595.39K)(2.46M)(7.38M)(7.96M)(43.32M)
Net Margin————-257.9%
EPS (Basic)(1.00)(4.26)(12.80)(13.54)(23.04)
EPS (Diluted)(1.00)(4.26)(12.80)(13.54)(23.04)
Weighted Avg Shares576.75K576.75K576.75K587.62K1.88M
Weighted Avg Shares (Diluted)576.75K576.75K576.75K587.62K1.88M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.